{"id":296018,"date":"2025-04-02T00:00:00","date_gmt":"2025-04-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0009-2024-biopharma-ulcerative-colitis-unmet-need-unmet-need-moderate-to-severe-ulcerative\/"},"modified":"2026-03-31T10:26:37","modified_gmt":"2026-03-31T10:26:37","slug":"unneim0009-2025-biopharma-ulcerative-colitis-unmet-need-unmet-need-moderate-to-severe-ulcerative-colitis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0009-2025-biopharma-ulcerative-colitis-unmet-need-unmet-need-moderate-to-severe-ulcerative-colitis-us-eu\/","title":{"rendered":"Ulcerative Colitis &#8211; Unmet Need &#8211; Unmet Need &#8211; Moderate to Severe Ulcerative Colitis (US\/EU)"},"content":{"rendered":"<p><abbr data-abbreviation-entity=\"4976\" title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors (Johnson &#038; Johnson Innovative Medicine \u2019s Remicade, AbbVie\u2019s Humira), a <abbr data-abbreviation-entity=\"4745\" title=\"cell adhesion molecule\">CAM<\/abbr> inhibitor (Takeda\u2019s Entyvio), a <abbr data-abbreviation-entity=\"7988\" title=\"Janus kinase\">JAK<\/abbr> inhibitor (Pfizer\u2019s Xeljanz), and an <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-12\/23 inhibitor (Johnson &#038; Johnson Innovative Medicine&#8217;s Stelara) are the mainstays of treatment for moderate to severe ulcerative colitis (<abbr title=\"ulcerative colitis\">UC<\/abbr>). However, these agents have safety risks and efficacy limitations. Newer alternatives, such as a <abbr data-abbreviation-entity=\"7988\" title=\"Janus kinase\">JAK<\/abbr> inhibitor (AbbVie\u2019s Rinvoq), <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-23 inhibitors (Eli Lilly\u2019s Omvoh, AbbVie\u2019s Skyrizi, and Johnson &#038; Johnson Innovative Medicine\u2019s Tremfya), and <abbr data-abbreviation-entity=\"5310\" title=\"sphingosine 1-phosphate\">S1P<\/abbr>-R modulators (<abbr data-abbreviation-entity=\"5794\" title=\"Bristol Myers Squibb\">BMS<\/abbr>\u2019s Zeposia and Pfizer\u2019s Velsipity) have expanded the treatment options, but significant unmet need remains for patients whose <abbr data-abbreviation-entity=\"4982\" title=\"ulcerative colitis\">UC<\/abbr> is refractory to these therapies. Emerging agents with novel mechanisms of action\u2014including anti-<abbr data-abbreviation-entity=\"10432\" title=\"tumor necrosis factor-like cytokine 1A\">TL1A<\/abbr> therapies and next-generation small molecules\u2014offer potential breakthroughs, but their long-term efficacy, safety, and positioning within the treatment paradigm remains to be seen.<\/p>\n<p><strong><strong>Questions answered<\/strong><\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals in moderate to severe <abbr data-abbreviation-entity=\"4982\" title=\"ulcerative colitis\">UC<\/abbr>?<\/li>\n<li>How do current therapies perform on treatment drivers and goals for moderate to severe <abbr data-abbreviation-entity=\"4982\" title=\"ulcerative colitis\">UC<\/abbr>?<\/li>\n<li>In addition to efficacy, which drug attributes most strongly influence physician prescribing behaviors, and which have a limited impact?<\/li>\n<li>What are the prevailing areas of unmet need and hidden opportunity in the treatment of moderate to severe <abbr data-abbreviation-entity=\"4982\" title=\"ulcerative colitis\">UC<\/abbr>?<\/li>\n<li>What trade-offs across clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new <abbr data-abbreviation-entity=\"4982\" title=\"ulcerative colitis\">UC<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61 U.S. and 32 European gastroenterologists, fielded in December 2024<\/p>\n<p><strong>Key companies:<\/strong> AbbVie, Johnson &#038; Johnson Innovative Medicine, Pfizer, Takeda, Eli Lilly, <abbr title=\"Bristol Myers Squibb\">BMS<\/abbr><\/p>\n<p><strong>Key drugs:<\/strong> Humira and biosimilars, Remicade and biosimilars, Entyvio, Stelara, Omvoh, Skyrizi, Tremfya, Rinvoq, Zeposia, Velsipity<\/p>\n<p><strong><strong>Product description<\/strong><\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-296018","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastrointestinal","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296018\/revisions"}],"predecessor-version":[{"id":575802,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296018\/revisions\/575802"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}